ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2371

Efficacy of First Line Biological Monotherapy in RA: Data from the Czech Registry Attra

Herman F. Mann1,2, Sarka Forejtova3, Katerina Jarosova4, Ladislav Senolt5, Jakub Zavada6, Michal Uher7, Karel Hejduk7 and Karel Pavelka8, 1Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, 21st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, 3Rheumatology, Institute of Rheumatology, Prague, Czech Republic, 4Na Slupi 4, Institute of Rheumatology, Prague, Czech Republic, 5Na Slupi 4, Revmatologicky ustav, Prague, Czech Republic, 6Charles University, Prague, Czech Republic, 7Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic, 8Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Biologic agents, registry, rheumatoid arthritis (RA) and therapy

  • Tweet
  • Email
  • Print
Session Information

Session Title: Rheumatoid Arthritis - Clinical Aspects (ACR): Impact of Various Interventions and Therapeutic Approaches

Session Type: Abstract Submissions (ACR)

Background/Purpose: The biological disease-modifying anti-rheumatic drugs (bDMARDs) should be used for the treatment of rheumatoid arthritis (RA) in combination with conventional synthetic DMARDs (csDMARDs). However a significant proportion of patients receive bDMARDs in monotherapy.

Methods: Baseline demographic data and efficacy parameters of the first bDMARD treatment of RA patients initiating bDMARD monotherapy (MONO) or combination (COMBI) therapy between 2007 and 2012 were retrieved from the national registry ATTRA. ATTRA is a centralized prospective computerized registry of patients receiving bDMARD therapy collecting data on efficacy, safety and quality of life of all patients treated with bDMARDs. bDMARD therapy was indicated after failure of at least 1 csDMARD (DAS28 ≥5.1).

Results: 1378 patients initiated bDMARD treatment after 2007,  prospective data regarding disease activity were available for 924 of them and this subgroup was further analyzed. The 114 patients (12%) who were started on bDMARD monotherapy were older (58 versus 52 years; P<0.001) with longer disease duration (10.1 versus 6.8 years; P=0.001) and more failed csDMARDs in the past (4 versus 3; P=0.002). The baseline DAS28 scores were similar in both groups (5.9 versus 5.8; P=0.083). The most commonly used first line bDMARDs in both groups were antiTNFα drugs (93.9% vs 94.4%; p=0.8). 61.4% MONO patients remained on the same therapy after 12 months, further 21.1% had a csDMARD added to their initial bDMARD. 75.3% COMBI patients remained on the original therapy, 9.7% more were on monotherapy with the first bDMARD. Remission (DAS28<2.6) was reached by 37.8% MONO patients and 41.6% COMBI patients after 12 months. Longitudinal binary logistic regression model was used to calculate the likelihood of reaching remission for both groups at various time points . 

M

o

n

t

h

 

Crude estimate

Adjusted estimate*

OR (95% IS)

P value

OR (95% IS)

P value

3

COMBI

reference

reference

MONO

0.59 (0.35;0.98)

0,041

0.60 (0.36;1.02)

0.059

6

COMBI

reference

reference

MONO

0.60 (0.37;0.98)

0,040

0.61 (0.37;1.01)

0.055

12

COMBI

reference

reference

MONO

0.68 (0.44;1.07)

0,093

0.67 (0.42;1.07)

0.093

*Adjusted for gender, age, disease duration, number of previous csDMARDs, glucocorticoid use and baseline DAS28.

 The median survival on the first bDMARD was 42.3 months in the MONO and 56.5 months in the COMBI group (HR 1.29; P=0.073) (Figure).

Conclusion: The results of this observational study suggest that bDMARD efficacy and retention is lower when used as monotherapy, however most observed differences did not reach statistical significance.

Acknowledgements: Supported by project 00023728 from MH CR

 


Disclosure:

H. F. Mann,
None;

S. Forejtova,
None;

K. Jarosova,
None;

L. Senolt,
None;

J. Zavada,
None;

M. Uher,
None;

K. Hejduk,
None;

K. Pavelka,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-of-first-line-biological-monotherapy-in-ra-data-from-the-czech-registry-attra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies